The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors
Open accessAbstract
Immunosuppressant drugs such as cyclosporin have allowed widespread organ transplantation, but their utility remains limited by toxicities, and they are ineffective in chronic management of autoimmune diseases such as multiple sclerosis. In contrast, the immune modulating drug FTY720 is efficacious in a variety of transplant and autoimmune models without inducing a generalized immunosuppressed state and is effective in human kidney transplantation. FTY720 elicits a lymphopenia resulting from a reversible redistribution of lymphocytes from circulation to secondary lymphoid tissues by unknown mechanisms. Using FTY720 and several analogs, we show now that FTY720 is phosphorylated by sphingosine kinase; the phosphorylated compound is a potent agonist at four sphingosine 1-phosphate receptors and represents the therapeutic principle in a rodent model of multiple sclerosis. Our results suggest that FTY720, after phosphorylation, acts through sphingosine 1-phosphate signaling pathways to modulate chemotactic responses and lymphocyte trafficking.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists
Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G.-J., Card, D., Keohane, C., et al. (2002) · Science · doi:10.1126/science.1070238 · Cited by 1,690
Apoptosis in neurodegenerative disorders
Mattson, M. P. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35040009 · Cited by 1,605
Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate
Cuvillier, O., Pirianov, G., Kleuser, B., Vanek, P. G., Coso, O. A., Gutkind, J. S., & Spiegel, S. (1996) · Nature · doi:10.1038/381800a0 · Cited by 1,529
Liu, Y., Wada, R., Yamashita, T., Mi, Y., Deng, C.-X., Hobson, J. P., Rosenfeldt, H. M., Nava, V. E., Chae, S.-S., Lee, M.-J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10905 · Cited by 1,149
Lee, M.-J., Thangada, S., Claffey, K. P., Ancellin, N., Liu, C. H., Kluk, M., Volpi, M., Sha'afi, R. I., & Hla, T. (1999) · Cell · doi:10.1016/s0092-8674(00)81661-x · Cited by 1,013
Liu, H., Sugiura, M., Nava, V. E., Edsall, L. C., Kono, K., Poulton, S., Milstien, S., Kohama, T., & Spiegel, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002759200 · Cited by 667
Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation.
Zhang, H., Desai, N. N., Olivera, A., Seki, T., Brooker, G., & Spiegel, S. (1991) · The Journal of cell biology · doi:10.1083/jcb.114.1.155 · Cited by 640
Chiba, K., Yanagawa, Y., Masubuchi, Y., Kataoka, H., Kawaguchi, T., Ohtsuki, M., & Hoshino, Y. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.10.5037 · Cited by 596
FUJITA, T., INOUE, K., YAMAMOTO, S., IKUMOTO, T., SASAKI, S., TOYAMA, R., CHIBA, K., HOSHINO, Y., & OKUMOTO, T. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.208 · Cited by 540
Lysophospholipids--Receptor Revelations
Hla, T., Lee, M.-J., Ancellin, N., Paik, J. H., & Kluk, M. J. (2001) · Science · doi:10.1126/science.1065323 · Cited by 537
Cited by
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1
Matloubian, M., Lo, C. G., Cinamon, G., Lesneski, M. J., Xu, Y., Brinkmann, V., Allende, M. L., Proia, R. L., & Cyster, J. G. (2004) · Nature · doi:10.1038/nature02284 · Cited by 2,581
Self-citationOral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Sphingosine-1-phosphate: an enigmatic signalling lipid
Spiegel, S., & Milstien, S. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1103 · Cited by 2,075
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Homing and cellular traffic in lymph nodes
von Andrian, U. H., & Mempel, T. R. (2003) · Nature Reviews Immunology · doi:10.1038/nri1222 · Cited by 1,281
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Self-citationNatural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Kappos, L., Antel, J., Comi, G., Montalban, X., O'Connor, P., Polman, C. H., Haas, T., Korn, A. A., Karlsson, G., & Radue, E. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052643 · Cited by 1,054
Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs
Cyster, J. G. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115628 · Cited by 856
Sphingosine 1-phosphate and cancer
Pyne, N. J., & Pyne, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2875 · Cited by 852
Sphingosine-1-Phosphate and Lymphocyte Egress from Lymphoid Organs
Cyster, J. G., & Schwab, S. R. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075011 · Cited by 815
Regulation of learning and memory by meningeal immunity: a key role for IL-4
Derecki, N. C., Cardani, A. N., Yang, C. H., Quinnies, K. M., Crihfield, A., Lynch, K. R., & Kipnis, J. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091419 · Cited by 800
Self-citationMechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
Lymphocyte Sequestration Through S1P Lyase Inhibition and Disruption of S1P Gradients
Schwab, S. R., Pereira, J. P., Matloubian, M., Xu, Y., Huang, Y., & Cyster, J. G. (2005) · Science · doi:10.1126/science.1113640 · Cited by 787
Lysophospholipid Receptors: Signaling and Biology
Ishii, I., Fukushima, N., Ye, X., & Chun, J. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073731 · Cited by 771
“Inside-Out” Signaling of Sphingosine-1-Phosphate: Therapeutic Targets
Takabe, K., Paugh, S. W., Milstien, S., & Spiegel, S. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07113 · Cited by 718
Sanna, M. G., Liao, J., Jo, E., Alfonso, C., Ahn, M.-Y., Peterson, M. S., Webb, B., Lefebvre, S., Chun, J., Gray, N., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311743200 · Cited by 626
The alliance of sphingosine-1-phosphate and its receptors in immunity
Rivera, J., Proia, R. L., & Olivera, A. (2008) · Nature Reviews Immunology · doi:10.1038/nri2400 · Cited by 616
Finding a way out: lymphocyte egress from lymphoid organs
Schwab, S. R., & Cyster, J. G. (2007) · Nature Immunology · doi:10.1038/ni1545 · Cited by 605
Choi, J. W., Gardell, S. E., Herr, D. R., Rivera, R., Lee, C.-W., Noguchi, K., Teo, S. T., Yung, Y. C., Lu, M., Kennedy, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014154108 · Cited by 581
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors
Gräler, M. H., & Goetzl, E. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-0910fje · Cited by 539
A regenerative approach to the treatment of multiple sclerosis
Deshmukh, V. A., Tardif, V., Lyssiotis, C. A., Green, C. C., Kerman, B., Kim, H. J., Padmanabhan, K., Swoboda, J. G., Ahmad, I., Kondo, T., et al. (2013) · Nature · doi:10.1038/nature12647 · Cited by 531
Brinkmann, V. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.04.006 · Cited by 528
Self-citationAn update on the biology of sphingosine 1-phosphate receptors
Blaho, V. A., & Hla, T. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046300 · Cited by 516
Protective Effects of Sphingosine 1-Phosphate in Murine Endotoxin-induced Inflammatory Lung Injury
Peng, X., Hassoun, P. M., Sammani, S., McVerry, B. J., Burne, M. J., Rabb, H., Pearse, D., Tuder, R. M., & Garcia, J. G. N. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200309-1258oc · Cited by 495
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
Steinman, L., & Zamvil, S. S. (2006) · Annals of Neurology · doi:10.1002/ana.20913 · Cited by 479
Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases
Hait, N. C., Oskeritzian, C. A., Paugh, S. W., Milstien, S., & Spiegel, S. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.08.007 · Cited by 478
Brinkmann, V., Cyster, J. G., & Hla, T. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00476.x · Cited by 478
Self-citationStructural and functional characteristics of S1P receptors
Sanchez, T., & Hla, T. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20127 · Cited by 456
Expression of the Sphingosine 1-Phosphate Receptor, S1P1, on T-cells Controls Thymic Emigration
Allende, M. L., Dreier, J. L., Mandala, S., & Proia, R. L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314291200 · Cited by 452
Mice Deficient in Sphingosine Kinase 1 Are Rendered Lymphopenic by FTY720
Allende, M. L., Sasaki, T., Kawai, H., Olivera, A., Mi, Y., van Echten-Deckert, G., Hajdu, R., Rosenbach, M., Keohane, C. A., Mandala, S., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406512200 · Cited by 447
Taylor, A. L., Watson, C. J. E., & Bradley, J. A. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.03.012 · Cited by 445
Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling
Chalfant, C. E., & Spiegel, S. (2005) · Journal of Cell Science · doi:10.1242/jcs.02637 · Cited by 444
T cells become licensed in the lung to enter the central nervous system
Odoardi, F., Sie, C., Streyl, K., Ulaganathan, V. K., Schläger, C., Lodygin, D., Heckelsmiller, K., Nietfeld, W., Ellwart, J., Klinkert, W. E. F., et al. (2012) · Nature · doi:10.1038/nature11337 · Cited by 442
Self-citationBrinkmann, V. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00451.x · Cited by 438
Self-citationTargeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond
Kunkel, G. T., Maceyka, M., Milstien, S., & Spiegel, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4099 · Cited by 434
Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases
Billich, A., Bornancin, F., Dévay, P., Mechtcheriakova, D., Urtz, N., & Baumruker, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307687200 · Cited by 433
Self-citationSphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone
Cinamon, G., Matloubian, M., Lesneski, M. J., Xu, Y., Low, C., Lu, T., Proia, R. L., & Cyster, J. G. (2004) · Nature Immunology · doi:10.1038/ni1083 · Cited by 418
Lung niches for the generation and maintenance of tissue-resident memory T cells
Turner, D. L., Bickham, K. L., Thome, J. J., Kim, C. Y., D'Ovidio, F., Wherry, E. J., & Farber, D. L. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.67 · Cited by 409
Oo, M. L., Thangada, S., Wu, M.-T., Liu, C. H., Macdonald, T. L., Lynch, K. R., Lin, C.-Y., & Hla, T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610318200 · Cited by 405
Self-citationSphingosine 1-Phosphate Receptor Signaling
Rosen, H., Gonzalez-Cabrera, P. J., Sanna, M. G., & Brown, S. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.072407.103733 · Cited by 404
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
Cohen, J. A., & Chun, J. (2011) · Annals of Neurology · doi:10.1002/ana.22426 · Cited by 393
Lysophospholipid receptors: Signalling, pharmacology and regulation by lysophospholipid metabolism
Meyer zu Heringdorf, D., & Jakobs, K. H. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.09.026 · Cited by 388
Physiological and pathological actions of sphingosine 1-phosphate
Hla, T. (2004) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2004.05.002 · Cited by 386
Sanchez, T., Estrada-Hernandez, T., Paik, J.-H., Wu, M.-T., Venkataraman, K., Brinkmann, V., Claffey, K., & Hla, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306896200 · Cited by 374
Self-citationPersistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors
Mullershausen, F., Zecri, F., Cetin, C., Billich, A., Guerini, D., & Seuwen, K. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.173 · Cited by 370
Erythrocytes store and release sphingosine 1‐phosphate in blood
Hänel, P., Andréani, P., & Gräler, M. H. (2007) · The FASEB Journal · doi:10.1096/fj.06-7433com · Cited by 361
Sphingosine Kinase Type 2 Is a Putative BH3-only Protein That Induces Apoptosis
Liu, H., Toman, R. E., Goparaju, S. K., Maceyka, M., Nava, V. E., Sankala, H., Payne, S. G., Bektas, M., Ishii, I., Chun, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304455200 · Cited by 356
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
Mehling, M., Brinkmann, V., Antel, J., Bar-Or, A., Goebels, N., Vedrine, C., Kristofic, C., Kuhle, J., Lindberg, R. L. P., & Kappos, L. (2008) · Neurology · doi:10.1212/01.wnl.0000327609.57688.ea · Cited by 345
Self-citationAn update on sphingosine-1-phosphate and other sphingolipid mediators
Fyrst, H., & Saba, J. D. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.392 · Cited by 344
The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR
Liu, G., Burns, S., Huang, G., Boyd, K., Proia, R. L., Flavell, R. A., & Chi, H. (2009) · Nature Immunology · doi:10.1038/ni.1743 · Cited by 339
“FTY720, a member of a new class of immunosuppressants in clinical trials for transplantation tolerance and multiple sclerosis, sequestrates T cells in lymphoid organs by acting on four of the five S1P receptor”
BackgroundNeviani, P., Santhanam, R., Oaks, J. J., Eiring, A. M., Notari, M., Blaser, B. W., Liu, S., Trotta, R., Muthusamy, N., Gambacorti-Passerini, C., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31095 · Cited by 335
Forrest, M., Sun, S.-Y., Hajdu, R., Bergstrom, J., Card, D., Doherty, G., Hale, J., Keohane, C., Meyers, C., Milligan, J., et al. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.062828 · Cited by 333
Chun, J., Hla, T., Lynch, K. R., Spiegel, S., & Moolenaar, W. H. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.003111 · Cited by 330
Self-citationPharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist
Iglarz, M., Binkert, C., Morrison, K., Fischli, W., Gatfield, J., Treiber, A., Weller, T., Bolli, M. H., Boss, C., Buchmann, S., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.142976 · Cited by 329
Sanchez, T., Skoura, A., Wu, M. T., Casserly, B., Harrington, E. O., & Hla, T. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.143735 · Cited by 328
Lysophospholipid receptor nomenclature review: IUPHAR Review 8
Kihara, Y., Maceyka, M., Spiegel, S., & Chun, J. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12678 · Cited by 324
Fukuhara, S., Simmons, S., Kawamura, S., Inoue, A., Orba, Y., Tokudome, T., Sunden, Y., Arai, Y., Moriwaki, K., Ishida, J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60746 · Cited by 324
Foster, C. A., Howard, L. M., Schweitzer, A., Persohn, E., Hiestand, P. C., Balatoni, B., Reuschel, R., Beerli, C., Schwartz, M., & Billich, A. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.127183 · Cited by 322
Self-citationChiba, K. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.002 · Cited by 321
Heckman, K. L., DeCoteau, W., Estevez, A., Reed, K. J., Costanzo, W., Sanford, D., Leiter, J. C., Clauss, J., Knapp, K., Gomez, C., et al. (2013) · ACS Nano · doi:10.1021/nn403743b · Cited by 320
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Ryu, J., Kim, H. J., Chang, E., Huang, H., Banno, Y., & Kim, H. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601430 · Cited by 317
Groves, A., Kihara, Y., & Chun, J. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.02.011 · Cited by 314
Kurobe, H., Liu, C., Ueno, T., Saito, F., Ohigashi, I., Seach, N., Arakaki, R., Hayashi, Y., Kitagawa, T., Lipp, M., et al. (2006) · Immunity · doi:10.1016/j.immuni.2005.12.011 · Cited by 311
Sphingosine 1-phosphate signalling
Mendelson, K., Evans, T., & Hla, T. (2014) · Development · doi:10.1242/dev.094805 · Cited by 309
Gergely, P., Nuesslein‐Hildesheim, B., Guerini, D., Brinkmann, V, Traebert, M., Bruns, C., Pan, S., Gray, N., Hinterding, K., Cooke, N., et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02061.x · Cited by 305
Self-citationThe immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2
Paugh, S. W., Payne, S. G., Barbour, S. E., Milstien, S., & Spiegel, S. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01168-2 · Cited by 302
Mast cell‐neural interactions contribute to pain and itch
Gupta, K., & Harvima, I. T. (2018) · Immunological Reviews · doi:10.1111/imr.12622 · Cited by 296
LaMontagne, K., Littlewood-Evans, A., Schnell, C., O'Reilly, T., Wyder, L., Sanchez, T., Probst, B., Butler, J., Wood, A., Liau, G., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2001 · Cited by 295
Multiple Sclerosis: Immunopathology and Treatment Update
Dargahi, N., Katsara, M., Tselios, T., Androutsou, M.-E., De Courten, M., Matsoukas, J., & Apostolopoulos, V. (2017) · Brain Sciences · doi:10.3390/brainsci7070078 · Cited by 285
Sphingolipids in inflammation: pathological implications and potential therapeutic targets
Nixon, G. F. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00281.x · Cited by 285
Lysophospholipid G Protein-coupled Receptors
Anliker, B., & Chun, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400013200 · Cited by 284
Signaling and biological actions of sphingosine 1-phosphate
Hla, T. (2003) · Pharmacological Research · doi:10.1016/s1043-6618(03)00046-x · Cited by 280
Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment
Fujino, M., Funeshima, N., Kitazawa, Y., Kimura, H., Amemiya, H., Suzuki, S., & Li, X.-K. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045658 · Cited by 280
Fingolimod provides long‐term protection in rodent models of cerebral ischemia
Wei, Y., Yemisci, M., Kim, H., Yung, L. M., Shin, H. K., Hwang, S., Guo, S., Qin, T., Alsharif, N., Brinkmann, V., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22186 · Cited by 277
Self-citationSphingosine 1-Phosphate Analogs as Receptor Antagonists
Davis, M. D., Clemens, J. J., Macdonald, T. L., & Lynch, K. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412356200 · Cited by 269
Self-citationSphingosine 1-phosphate and inflammation
Obinata, H., & Hla, T. (2019) · International Immunology · doi:10.1093/intimm/dxz037 · Cited by 268
Sugimoto, N., Takuwa, N., Okamoto, H., Sakurada, S., & Takuwa, Y. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.5.1534-1545.2003 · Cited by 264
Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720
Zemann, B., Kinzel, B., Müller, M., Reuschel, R., Mechtcheriakova, D., Urtz, N., Bornancin, F., Baumruker, T., & Billich, A. (2006) · Blood · doi:10.1182/blood-2005-07-2628 · Cited by 264
Self-citationBrinkmann, V., & Lynch, K. R. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00374-6 · Cited by 262
Self-citationInflammatory Responses in Brain Ischemia
Kawabori, M., & Yenari, M. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150209154036 · Cited by 262
Lysophospholipids and their receptors in the central nervous system
Choi, J. W., & Chun, J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.07.015 · Cited by 255
Industrial natural product chemistry for drug discovery and development
Bauer, A., & Brönstrup, M. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70058e · Cited by 255
Pharmacologic Treatment of Acute Kidney Injury: Why Drugs Haven’t Worked and What Is on the Horizon
Jo, S. K., Rosner, M. H., & Okusa, M. D. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03280906 · Cited by 252
Wheeler, D., Bandaru, V. V. R., Calabresi, P. A., Nath, A., & Haughey, N. J. (2008) · Brain · doi:10.1093/brain/awn190 · Cited by 171
“This orally available S1P-receptor modulator has shown striking efficacy in experimental allergic encephalomyelitis models of multiple sclerosis (Brinkmann et al., 2002; Fujino et al., 2003; Webb et al., 2004 Kataoka et al., 2005; Balatoni et al., 2007) and recent results from phase II trials with…”
BackgroundLoss of the neuroprotective factor sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis
Couttas, T. A., Kain, N., Daniels, B., Lim, X. Y., Shepherd, C., Kril, J., Pickford, R., Li, H., Garner, B., & Don, A. S. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-9 · Cited by 161
“FTY720 is a synthetic analogue of sphingosine that is rapidly phosphorylated by SphK2 in vivo, forming the S1P mimetic FTY720-phosphate, which is a highly potent agonist of receptors S1P1, S1P3, S1P4 and S1P5 [27,29].”
BackgroundChun, J., Kihara, Y., Jonnalagadda, D., & Blaho, V. A. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021358 · Cited by 131
“Basic science studies on the MOA for FTY720 identified the phosphorylated metabolite FTY720P as a receptor agonist for multiple S1P receptor subtypes (S1P1,3,4,5) (84, 85).”
BackgroundInfluentialMutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization
Liu, Z., Yoshimi, A., Wang, J., Cho, H., Chun-Wei Lee, S., Ki, M., Bitner, L., Chu, T., Shah, H., Liu, B., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1330 · Cited by 118
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis
Piehl, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13215 · Cited by 125
Finding a way out: S1P signaling and immune cell migration
Baeyens, A. A. L., & Schwab, S. R. (2020) · Annual Review of Immunology · doi:10.1146/annurev-immunol-081519-083952 · Cited by 123
Vascular and immunobiology of the circulatory sphingosine 1-phosphate gradient
Yanagida, K., & Hla, T. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021014-071635 · Cited by 109
Tomura, H., Wang, J.-Q., Komachi, M., Damirin, A., Mogi, C., Tobo, M., Kon, J., Misawa, N., Sato, K., & Okajima, F. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505287200 · Cited by 103
Slowik, A., Schmidt, T., Beyer, C., Amor, S., Clarner, T., & Kipp, M. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12938 · Cited by 94
Sphingosine 1-phosphate signaling in bone remodeling: multifaceted roles and therapeutic potential
Meshcheryakova, A., Mechtcheriakova, D., & Pietschmann, P. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1332180 · Cited by 74
Schaper, K., Dickhaut, J., Japtok, L., Kietzmann, M., Mischke, R., Kleuser, B., & Bäumer, W. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.03.006 · Cited by 68
Sphingosine 1-phosphate is a key metabolite linking sphingolipids to glycerophospholipids
Kihara, A. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.08.014 · Cited by 65
Metadata
- Authors
- Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., Foster, C. A., Zollinger, M., & Lynch, K. R.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-06
- Volume
- 277
- Issue
- 24
- Pages
- 21453-21457
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2154089780
- Cited by
- 1,504
- References
- 32
- FWCI
- 19.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.